slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 209,071-209,100
Pages 10,126
Rows per page 30
Component
209,071-209,100 of 303,780
07
The slide uses a numbered list for the thesis points and a separate callout box for milestones.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
08
The slide uses a Gantt-chart style visualization to show the progress of multiple drug candidates across clinical phases.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
09
Includes specific financial terms of the collaboration and regulatory milestones.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
10
The slide uses a structured layout to compare three distinct product pipelines.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
11
The slide uses a two-tier layout to distinguish between Phase 1 and Preclinical development stages.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
12
The slide uses a process-like flow to connect internal strengths to external market validation.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
14
Dare Bioscience | Investor Presentation Deck | 54 slidesDare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
16
Slide 16 of a pitch deck.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
17
The slide uses a structured comparison format to frame the medical problem and the proposed solution.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
18
Mentions Organon as the commercial partner leveraging the NEXPLANON sales team.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
19
The slide highlights a key partnership milestone and the associated financial structure (upfront payment and potential milestones).Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
20
Standard pharmaceutical ISI (Important Safety Information) slide.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
21
This is a regulatory disclosure slide regarding drug safety in specific patient demographics.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
23
Includes a line chart of population projections and three circular callouts detailing specific product sales.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
24
The slide uses a tree-like diagram to segment the total addressable market into specific contraceptive user groups.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
25
The slide uses a vertical axis to represent effectiveness, positioning the company's product as a bridge between traditional barrier methods and the Copper IUD.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
26
The slide uses a comparison table structure to map desired product features to specific Ovaprene design attributes.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
27
Includes details on milestone payments, royalties, and strategic support from Bayer.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
28
Includes a testimonial quote from a Bayer executive.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
29
Includes a data table comparing baseline PCT results with Ovaprene PCT results.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
30
The slide highlights the lack of existing FDA-approved therapies for FSAD.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
31
Uses a visual inequality symbol to emphasize the distinction between FSAD and HSDD.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
32
The slide uses a double-bordered box design to separate academic meta-analysis from commercial market research estimates.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
33
The slide uses a light blue callout box to group the product benefits and highlights the lack of current FDA-approved treatments for FSAD.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
34
The slide outlines the methodology and goals of a clinical trial, specifically mentioning the RESPOND study.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
35
The slide uses clinical trial data to justify the pivot to a topical delivery mechanism.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
36
Includes a table of pharmacokinetic parameters and a line chart showing plasma concentration over time.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
37
Study design is a small N=6 crossover trial.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
38
Dare Bioscience | Investor Presentation Deck | 54 slidesDare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
39
The slide uses a side-by-side comparison layout to contrast the biological route with the technical solution.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit